Methylprednisolone and Leflunomide Together: What FDA Data Reveals About This Combination

Maria, a 58-year-old with moderate rheumatoid arthritis, walked into her rheumatologist's office expecting to start leflunomide—a disease-modifying antirheumatic drug (DMARD) known for slowing joint damage. But her chart already showed methylprednisolone, a corticosteroid her primary care doctor had prescribed three months earlier for a flare-up of polymyalgia rheumatica. Maria's pharmacist flagged the prescription, noting that combining these two immunosuppressant drugs wasn't explicitly forbidden—but it required careful monitoring. "Is this safe?" Maria asked. The answer, as with many real-world drug combinations, is nuanced: possible, but risky without proper oversight.

When two powerful drugs that suppress the immune system are used together, the stakes are high. This post explains what the FDA label data tells us about methylprednisolone and leflunomide, why this combination demands caution, and what you need to do if you're taking both.

Overview: Two Immunosuppressants, One Body

Methylprednisolone is a corticosteroid used to reduce inflammation and suppress immune responses. It's prescribed for autoimmune conditions, inflammatory disorders, and acute flare-ups. Leflunomide is a DMARD designed specifically for rheumatoid arthritis and other autoimmune conditions; it works by suppressing T-cell activation in the immune system.

Both drugs work by dampening immune function—but they do so via different mechanisms. This raises an important pharmacological question: when stacked, do their immunosuppressive effects compound, and if so, to what degree?

What the FDA Says

The U.S. FDA label for methylprednisolone does not list leflunomide as a contraindicated drug. Similarly, the FDA label for leflunomide does not explicitly flag methylprednisolone as unsafe. However, absence of a specific warning does not equal absence of risk.

What the labels do say is instructive:

• Methylprednisolone FDA label: Warns that corticosteroids increase susceptibility to infections, can cause immunosuppression, and may reactivate latent infections (tuberculosis, fungal infections, viral infections). The label advises caution when used with other immunosuppressive agents.
• Leflunomide FDA label: Warns of serious infections, hepatotoxicity, bone marrow suppression, and teratogenicity. The label notes that leflunomide should be used with caution in patients with immunosuppression and states that combining it with other immunosuppressive drugs increases the risk of infection.

In FDA FAERS (Adverse Event Reporting System) data, individual case reports document serious infections, bone marrow disorders, and liver toxicity when patients were on multiple immunosuppressive agents including corticosteroids and DMARDs. While a direct causal link cannot always be established from FAERS alone, the pattern is clear: dual immunosuppression carries documented risk.

Severity and Risk Level: Why This Matters

The primary concern with combining methylprednisolone and leflunomide is additive immunosuppression. Here's what that means:

• Increased infection risk: Both drugs lower immune surveillance. Combined, they can elevate the risk of serious, opportunistic infections—including tuberculosis, fungal infections (Pneumocystis pneumonia, histoplasmosis), and atypical viral infections. These infections can become life-threatening if not caught early.
• Bone marrow suppression: Leflunomide can cause anemia, thrombocytopenia, and leukopenia. Methylprednisolone can mask symptoms of blood cell abnormalities. Together, monitoring becomes critical.
• Hepatotoxicity: Leflunomide is metabolized by the liver and can cause elevated liver enzymes or hepatitis. Corticosteroids, while not primarily hepatotoxic, can complicate liver function in patients already at risk.
• Drug clearance: Methylprednisolone can induce certain metabolic pathways, potentially affecting leflunomide's elimination—though this mechanism is not fully characterized and varies by individual.

From a severity standpoint, this is best classified as a moderate-to-major combination. It's not absolutely contraindicated, but it requires baseline testing, ongoing monitoring, and physician oversight. A patient cannot simply start both drugs and assume they'll be fine.

Who Is Most at Risk

Certain patients face higher risk with this combination:

• Elderly patients: Immune function declines naturally with age; adding dual immunosuppression amplifies infection risk.
• Patients with a history of infection: Those who've had tuberculosis, hepatitis, or recurrent infections should be approached with extra caution.
• Patients with liver disease: Pre-existing hepatic impairment makes leflunomide less suitable and corticosteroids potentially more risky.
• Patients on other medications: Antifungals, antivirals, and additional immunosuppressive therapies compound the risk.
• Pregnant or nursing women: Leflunomide is teratogenic and requires strict contraception; corticosteroids in pregnancy carry their own risks. This combination should be avoided in these groups.

What to Do: Practical Guidance

If you're currently taking both methylprednisolone and leflunomide, or if you've been prescribed both:

• Do not stop either drug on your own. Abrupt cessation—particularly of methylprednisolone—can cause withdrawal symptoms or flare-up of the underlying condition.
• Contact your pharmacist immediately. Ask specifically about this combination. Your pharmacist can access your full medication history and identify other interactions you might not realize.
• Request baseline testing before starting leflunomide: Complete blood count (CBC), liver function tests (LFTs), and urinalysis should be done. If you're already on methylprednisolone, these should be completed beforehand.
• Establish a monitoring schedule: Your physician should arrange regular blood work—typically every 4–12 weeks—to watch for bone marrow suppression, liver dysfunction, and other warning signs.
• Report symptoms promptly: Unusual fatigue, unexplained fever, persistent sore throat, easy bruising, yellowing skin/eyes, or dark urine warrant immediate medical attention.
• Discuss tapering strategies: If your autoimmune condition stabilizes, ask your doctor about gradually reducing methylprednisolone dosage. Lower corticosteroid doses reduce immunosuppression and may allow safer concurrent leflunomide therapy.

When to Call Your Doctor

Seek immediate medical attention if you experience:

• Fever (temperature above 100.4°F / 38°C), especially if prolonged or recurrent
• Persistent cough, shortness of breath, or chest pain
• Severe fatigue or unexplained weakness
• Unusual bleeding, bruising, or petechiae (small red dots on skin)
• Jaundice (yellowing of skin or eyes) or dark urine
• Abdominal pain or swelling
• Signs of infection at wounds or injection sites
• Any symptom that feels unusual or concerning

Do not assume a symptom is minor. Immunosuppressed patients can deteriorate rapidly if infection takes hold.

Bottom Line

Methylprednisolone and leflunomide are not absolutely contraindicated together, but they represent a moderate-to-major interaction that demands respect and careful medical management. Both drugs suppress immune function, and when combined, the risk of serious infection, bone marrow disorders, and liver toxicity increases measurably. The FDA labels reflect this caution, and real-world adverse event data underscores the importance of baseline testing and ongoing monitoring.

Many patients do take corticosteroids and DMARDs together successfully—rheumatologists do this by necessity in severe autoimmune disease. Success depends on three things: baseline assessment, close monitoring, and prompt reporting of symptoms.

If you're taking methylprednisolone and leflunomide together, or if you've been newly prescribed this combination, your next step is clear: contact your pharmacist to review your full medication profile and discuss monitoring requirements with your doctor. Your safety depends on transparency and partnership with your healthcare team.

Don't leave medication safety to chance. Use checkdruginteractions.com—the most comprehensive drug interaction checker on the internet, powered by over 250,000 FDA-labeled drug records—to verify your complete medication list. Enter up to 20 drugs at once, get instant, FDA-sourced interaction data, and ensure your pharmacy and doctor are aligned on your care. Check now, anytime, no account required.